Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary Central Nervous System Lymphoma

NCT05998642 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT05998642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05998642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary Central Nervous System Lymphoma
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 2
Overall status
Recruiting
Start date
February 13, 2024
Completion date
December 31, 2028
Enrollment
30 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma